Cancer Risk in Mycophenolate-Treated Patients Differs by Indication

Cancer Risk in Mycophenolate-Treated Patients Differs by Indication

A retrospective review shows that dermatologic patients treated with mycophenolate mofetil face a significantly lower incidence of malignancy than transplant recipients.

Cancer Risk in MMF-Treated Patients Differs by Indication

TOPLINE:  Patients with dermatologic conditions showed a 74% lower risk for malignancy with mycophenolate mofetil (MMF) than transplant patients, a study found. METHODOLOGY: Researchers conducted a single-center retrospective chart of patients who had taken MMF for ≥ 5 years between 2012 and 2025 at Atrium Health Wake Forest Baptist Medical Center. The analysis included 126 […] The post Cancer Risk in MMF-Treated Patients Differs by Indication f…